Aefi Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Health Ministry issues advisory of potential thromboembolic incidents
Adverse Event Following Immunisation (AEFI) data in India showed that there is a minuscule but definitive risk of thromboembolic events after the AstraZeneca-Oxford vaccine (Covishield in India).
A statement issued by the Health Ministry on Monday noted that the reporting rate of these events in India is around 0.61/million doses, which is much lower than the four cases/million reported by UK’s regulator Medical and Health Regulatory Authority (MHRA). Germany has reported 10 events per million doses.
There were no potential thromboembolic events reported following administration of Covaxin vaccine.
Bleeding and clotting cases following COVID vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country, a report submitted by the National AEFI to the Health Ministry noted. ....

United Kingdom , Health Regulatory Authority , Health Ministry On , Health Ministry , Adverse Event Following Immunisation , Southeast Asian , Health Care Workers , Vaccine Beneficiaries , Covishield Blood Clotting , Covishield Bleeding , Aefi Data , Thromboembolic Events , Astrazeneca Oxford Vaccine , ஒன்றுபட்டது கிஂக்டம் , ஆரோக்கியம் ஒழுங்குமுறை அதிகாரம் , ஆரோக்கியம் அமைச்சகம் ஆன் , ஆரோக்கியம் அமைச்சகம் , தென்கிழக்கு ஆசிய , ஆரோக்கியம் பராமரிப்பு தொழிலாளர்கள் ,